Cargando…

Cost-effectiveness of pharmacist care for managing hypertension in Canada

BACKGROUND: More than half of all heart disease and stroke are attributable to hypertension, which is associated with approximately 10% of direct medical costs globally. Clinical trial evidence has demonstrated that the benefits of pharmacist intervention, including education, consultation and/or pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Marra, Carlo, Johnston, Karissa, Santschi, Valerie, Tsuyuki, Ross T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415065/
https://www.ncbi.nlm.nih.gov/pubmed/28507654
http://dx.doi.org/10.1177/1715163517701109
_version_ 1783233462076964864
author Marra, Carlo
Johnston, Karissa
Santschi, Valerie
Tsuyuki, Ross T.
author_facet Marra, Carlo
Johnston, Karissa
Santschi, Valerie
Tsuyuki, Ross T.
author_sort Marra, Carlo
collection PubMed
description BACKGROUND: More than half of all heart disease and stroke are attributable to hypertension, which is associated with approximately 10% of direct medical costs globally. Clinical trial evidence has demonstrated that the benefits of pharmacist intervention, including education, consultation and/or prescribing, can help to reduce blood pressure; a recent Canadian trial found an 18.3 mmHg reduction in systolic blood pressure associated with pharmacist care and prescribing. The objective of this study was to evaluate the economic impact of such an intervention in a Canadian setting. METHODS: A Markov cost-effectiveness model was developed to extrapolate potential differences in long-term cardiovascular and renal disease outcomes, using Framingham risk equations and other published risk equations. A range of values for systolic blood pressure reduction was considered (7.6-18.3 mmHg) to reflect the range of potential interventions and available evidence. The model incorporated health outcomes, costs and quality of life to estimate an overall incremental cost-effectiveness ratio. Costs considered included direct medical costs as well as the costs associated with implementing the pharmacist intervention strategy. RESULTS: For a systolic blood pressure reduction of 18.3 mmHg, the estimated impact is 0.21 fewer cardiovascular events per person and, discounted at 5% per year, 0.3 additional life-years, 0.4 additional quality-adjusted life-years and $6,364 cost savings over a lifetime. Thus, the intervention is economically dominant, being both more effective and cost-saving relative to usual care. DISCUSSION: Across a range of one-way and probabilistic sensitivity analyses of key parameters and assumptions, pharmacist intervention remained both effective and cost-saving. CONCLUSION: Comprehensive pharmacist care of hypertension, including patient education and prescribing, has the potential to offer both health benefits and cost savings to Canadians and, as such, has important public health implications.
format Online
Article
Text
id pubmed-5415065
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-54150652017-05-15 Cost-effectiveness of pharmacist care for managing hypertension in Canada Marra, Carlo Johnston, Karissa Santschi, Valerie Tsuyuki, Ross T. Can Pharm J (Ott) Research and Clinical BACKGROUND: More than half of all heart disease and stroke are attributable to hypertension, which is associated with approximately 10% of direct medical costs globally. Clinical trial evidence has demonstrated that the benefits of pharmacist intervention, including education, consultation and/or prescribing, can help to reduce blood pressure; a recent Canadian trial found an 18.3 mmHg reduction in systolic blood pressure associated with pharmacist care and prescribing. The objective of this study was to evaluate the economic impact of such an intervention in a Canadian setting. METHODS: A Markov cost-effectiveness model was developed to extrapolate potential differences in long-term cardiovascular and renal disease outcomes, using Framingham risk equations and other published risk equations. A range of values for systolic blood pressure reduction was considered (7.6-18.3 mmHg) to reflect the range of potential interventions and available evidence. The model incorporated health outcomes, costs and quality of life to estimate an overall incremental cost-effectiveness ratio. Costs considered included direct medical costs as well as the costs associated with implementing the pharmacist intervention strategy. RESULTS: For a systolic blood pressure reduction of 18.3 mmHg, the estimated impact is 0.21 fewer cardiovascular events per person and, discounted at 5% per year, 0.3 additional life-years, 0.4 additional quality-adjusted life-years and $6,364 cost savings over a lifetime. Thus, the intervention is economically dominant, being both more effective and cost-saving relative to usual care. DISCUSSION: Across a range of one-way and probabilistic sensitivity analyses of key parameters and assumptions, pharmacist intervention remained both effective and cost-saving. CONCLUSION: Comprehensive pharmacist care of hypertension, including patient education and prescribing, has the potential to offer both health benefits and cost savings to Canadians and, as such, has important public health implications. SAGE Publications 2017-03-21 /pmc/articles/PMC5415065/ /pubmed/28507654 http://dx.doi.org/10.1177/1715163517701109 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research and Clinical
Marra, Carlo
Johnston, Karissa
Santschi, Valerie
Tsuyuki, Ross T.
Cost-effectiveness of pharmacist care for managing hypertension in Canada
title Cost-effectiveness of pharmacist care for managing hypertension in Canada
title_full Cost-effectiveness of pharmacist care for managing hypertension in Canada
title_fullStr Cost-effectiveness of pharmacist care for managing hypertension in Canada
title_full_unstemmed Cost-effectiveness of pharmacist care for managing hypertension in Canada
title_short Cost-effectiveness of pharmacist care for managing hypertension in Canada
title_sort cost-effectiveness of pharmacist care for managing hypertension in canada
topic Research and Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415065/
https://www.ncbi.nlm.nih.gov/pubmed/28507654
http://dx.doi.org/10.1177/1715163517701109
work_keys_str_mv AT marracarlo costeffectivenessofpharmacistcareformanaginghypertensionincanada
AT johnstonkarissa costeffectivenessofpharmacistcareformanaginghypertensionincanada
AT santschivalerie costeffectivenessofpharmacistcareformanaginghypertensionincanada
AT tsuyukirosst costeffectivenessofpharmacistcareformanaginghypertensionincanada